Diversified Trust Co Lowers Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Diversified Trust Co cut its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 27.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 15,795 shares of the biotechnology company’s stock after selling 5,885 shares during the quarter. Diversified Trust Co’s holdings in BioCryst Pharmaceuticals were worth $119,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. The Manufacturers Life Insurance Company grew its holdings in BioCryst Pharmaceuticals by 40.7% in the third quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock valued at $2,274,000 after purchasing an additional 86,571 shares during the period. Counterweight Ventures LLC lifted its position in BioCryst Pharmaceuticals by 591.7% during the third quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock valued at $710,000 after buying an additional 79,884 shares in the last quarter. XTX Topco Ltd lifted its position in BioCryst Pharmaceuticals by 299.0% during the second quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company’s stock valued at $970,000 after buying an additional 117,607 shares in the last quarter. Seven Eight Capital LP lifted its position in BioCryst Pharmaceuticals by 1,407.1% during the second quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock valued at $1,048,000 after buying an additional 158,358 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after buying an additional 375,890 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BCRX. Barclays lifted their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Needham & Company LLC reissued a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $15.60.

BioCryst Pharmaceuticals Trading Down 4.7 %

NASDAQ BCRX opened at $7.67 on Monday. The company’s fifty day simple moving average is $7.59 and its 200-day simple moving average is $7.59. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.88. The stock has a market cap of $1.59 billion, a P/E ratio of -12.57 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. The company’s revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.19) earnings per share. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.